Chemotherapy plus pembrolizumab before surgery for high-risk triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two different sequences of chemotherapy combined with pembrolizumab (an immunotherapy drug) given before surgery for high-risk triple-negative breast cancer. The goal is to see which sequence works better at shrinking or eliminating the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with triple-negative breast cancer (a type that does not have receptors for estrogen, progesterone, or HER2).
- Your tumor is at least 10% infiltrated by immune cells (called stromal tumor-infiltrating lymphocytes).
- Your cancer has not spread to other parts of the body and is at a certain stage (T1c with lymph node involvement, or T2-T4 with any lymph node status up to N2).
- You have not had chemotherapy, targeted therapy, or radiation for this cancer before.
- You have good overall health (ECOG performance status 0 or 1) and adequate heart and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests if giving more of the immunotherapy drug pembrolizumab (Keytruda) after surgery helps people with early-stage triple-negative breast cancer that did not completely disappear with the initial chemotherapy plus immunotherapy. This is for patients who still have some cancer left after surgery, to reduce the chance of it coming back.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.